Advertising
Showing 1 to 15 of 167 entries
BUY
Likes this pharma. It offers decent dividend growth and the dividend is safe. He holds pharma long term and didn't sell during Covid. Post-Covid, focus will return to non-Covid drugs, like BMY's cancer treatment.
biotechnology / pharmaceutical
BUY
Up 9.5% for the year, and is benefiting from the expected decree from Washington for Covid booster shots to fight Covid. So, BMY is rising because the entire drug space is rising. They also have a consistent track record, consistent dividend and anti-cancer drug.
biotechnology / pharmaceutical
COMMENT
They report Friday. He likes the CEO, but isn't sure if this stock can break from the pack.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jan 22/20, Down 8%) Sexier areas of the market pulled money away from the boring companies. Over the next decade, sees a fantastic R&D pipeline of cancer drugs. Tremendous cashflow will be deployed in R&D and acquisitions to augment their growth profile. Stick with it to collect the dividend with some slow growth.
biotechnology / pharmaceutical
HOLD

Diversified large cap. A lot of businesses working really well. Celgene acquisition diversified their oncology. Main drug is performing well. Trading at 8.5x forward earnings, with low double digit EPS growth. One of his core holdings.

biotechnology / pharmaceutical
BUY

It was up nearly 4% today during JPMorgan's healthcare conference. BMY delivered good news. Management announced strong early revenue goals for new products, including three new drugs that could hit $4 billion in sales this decade. Their strong pipeline of drugs was bulked by buying Celgene and MyoKardia. They also announced a bullish free cash-flow forecasts for coming years which will buyback shares and pay down debt. For years, this has failed to break out from mid-$60s, but that could change.

biotechnology / pharmaceutical
TOP PICK

He liked their Celgene acquisition last year (though the market didn't), because it diversified their exposure to other drugs which have exectued well. Their R&D and core business are doing well. The stock trades at only 8x earnings. There is a disconnect between company performance and the market. It's very cheap and they execute well. (Analysts’ price target is $72.93)

biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly This household pharma player has just made a $13 billion acquisition of a company that focuses on the treatment of irregular heart rhythms -- something that doesn't have another treatment option yet. This will go to diversify the company's success in the cancer treatment field. With an outlook to earnings growth of over 17% next year the Price to Earnings Growth Ratio is just 1.1 -- suggesting good value at these levels. We would trade this with a $54 stop-loss. Yield 3.04% (Analysts’ price target is $73.62)
biotechnology / pharmaceutical
TOP PICK
There is so much value in drug companies. His model price is $111, or a 90% upside on this one. It may be suffering a little from maybe Biden winning the election. It pays 3% while interest rates are zero. There is not much downside. (Analysts’ price target is $72.79)
biotechnology / pharmaceutical
BUY

MyoKardia deal: https://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash Today BMY announced it's buying MyoKardia (MYOK-Q) ifor US$13.1 billion cash. MyoKardia makes drugs to fight heart disease and heart conditions, including mavacamten, a drug for which they will file an application in Q1-2021. The stock has gotten really cheap. He loves this deal.

biotechnology / pharmaceutical
TOP PICK
He has a model price over $111 -- a 95% upside opportunity. Yield 3.13% (Analysts’ price target is $66.94)
biotechnology / pharmaceutical
DON'T BUY
They are focused on the drug side of health care. There is a lot pressure on costs and from a political perspective as well. The company has had a great run as of late, but drugs can be very volatile. He generally favors the equipment and insurance sectors in health care.
biotechnology / pharmaceutical
TOP PICK

A leading oncology drug producer, trading at 10x earnings and paying a 3% dividend. Many catalysts are coming. They merged with Celgene, a deal which has raised investor expectations, with potentially strong synergies. This could trade at 11x earnings. You can make 20% on this. Holding a healthcare name is key. (Analysts’ price target is $71.64)

biotechnology / pharmaceutical
COMMENT
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
biotechnology / pharmaceutical
COMMENT

They're getting a good deal on Celgene. Can't say what he'll do with this stock, but BMY is attractive.

biotechnology / pharmaceutical
Showing 1 to 15 of 167 entries

Bristol Myers Squibb(BMY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 6

Stockchase rating for Bristol Myers Squibb is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bristol Myers Squibb(BMY-N) Frequently Asked Questions

What is Bristol Myers Squibb stock symbol?

Bristol Myers Squibb is a American stock, trading under the symbol BMY-N on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY-N

Is Bristol Myers Squibb a buy or a sell?

In the last year, 6 stock analysts published opinions about BMY-N. 5 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bristol Myers Squibb.

Is Bristol Myers Squibb a good investment or a top pick?

Bristol Myers Squibb was recommended as a Top Pick by on . Read the latest stock experts ratings for Bristol Myers Squibb.

Why is Bristol Myers Squibb stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bristol Myers Squibb worth watching?

6 stock analysts on Stockchase covered Bristol Myers Squibb In the last year. It is a trending stock that is worth watching.

What is Bristol Myers Squibb stock price?

On 2021-10-19, Bristol Myers Squibb (BMY-N) stock closed at a price of $57.44.